BFA
SCLN

BlackRock Fund Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

BlackRock Fund Advisors’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$49.5M Sell
4,581,672
-276,603
-6% -$2.77M 0.01% 1696
2016
Q3 		$49.8M Buy
4,858,275
+354,655
+8% +$3.86M 0.01% 1581
2016
Q2 		$58.8M Buy
4,503,620
+2,548,007
+130% +$33.4M 0.01% 1386
2016
Q1 		$21.5M Buy
1,955,613
+19,760
+1% +$176K 0.01% 1950
2015
Q4 		$17.8M Sell
1,935,853
-106,317
-5% -$890K ﹤0.01% 2119
2015
Q3 		$14.2M Buy
2,042,170
+57,670
+3% +$494K ﹤0.01% 2207
2015
Q2 		$19.5M Sell
1,984,500
-122,432
-6% -$1.12M ﹤0.01% 2129
2015
Q1 		$18.7M Buy
2,106,932
+52,460
+3% +$418K ﹤0.01% 2114
2014
Q4 		$18M Buy
2,054,472
+172,422
+9% +$1.4M ﹤0.01% 2125
2014
Q3 		$13M Sell
1,882,050
-40,570
-2% -$243K ﹤0.01% 2205
2014
Q2 		$10.1M Sell
1,922,620
-263,431
-12% -$1.28M ﹤0.01% 2411
2014
Q1 		$9.95M Buy
2,186,051
+80,672
+4% +$390K ﹤0.01% 2402
2013
Q4 		$10.6M Sell
2,105,379
-24,559
-1% -$118K ﹤0.01% 2357
2013
Q3 		$10.8M Buy
2,129,938
+267,771
+14% +$1.49M ﹤0.01% 2312
2013
Q2 		$9.24M Buy
+1,862,167
New +$8.86M ﹤0.01% 2296

Other funds holding SCLN

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

BlackRock Fund Advisors's SCLN Position: Q4 2016 in Review

BlackRock Fund Advisors reduced its Sciclone Pharmaceuticals Inc (SCLN) stake by 5.7% in Q4 2016, selling an estimated $2.77M and leaving 4,581,672 shares worth $49.5M. The position accounts for 0.01% of the portfolio, ranked #1696.

BlackRock Fund Advisors first reported a position in SCLN in Q2 2013 and has held it in 15 quarters since. The position peaked at $58.8M in Q2 2016. 153 funds tracked by Wall St. Rank hold SCLN as of Q4 2016.

  • BlackRock Fund Advisors held 4,581,672 shares of Sciclone Pharmaceuticals Inc worth $49.5M as of Q4 2016.
  • BlackRock Fund Advisors sold 276,603 Sciclone Pharmaceuticals Inc shares in Q4 2016, an estimated $2.77M.
  • Sciclone Pharmaceuticals Inc made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1696 holding.
  • BlackRock Fund Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Fund Advisors's Sciclone Pharmaceuticals Inc position peaked at $58.8M in Q2 2016.
  • 153 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.